NO2945854T3 - - Google Patents

Info

Publication number
NO2945854T3
NO2945854T3 NO13811985A NO13811985A NO2945854T3 NO 2945854 T3 NO2945854 T3 NO 2945854T3 NO 13811985 A NO13811985 A NO 13811985A NO 13811985 A NO13811985 A NO 13811985A NO 2945854 T3 NO2945854 T3 NO 2945854T3
Authority
NO
Norway
Application number
NO13811985A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2945854T3 publication Critical patent/NO2945854T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO13811985A 2012-03-01 2013-12-23 NO2945854T3 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261605523P 2012-03-01 2012-03-01

Publications (1)

Publication Number Publication Date
NO2945854T3 true NO2945854T3 (zh) 2018-07-21

Family

ID=47892024

Family Applications (1)

Application Number Title Priority Date Filing Date
NO13811985A NO2945854T3 (zh) 2012-03-01 2013-12-23

Country Status (36)

Country Link
US (4) US8697715B2 (zh)
EP (2) EP3321262B1 (zh)
JP (2) JP6068515B2 (zh)
KR (1) KR102093526B1 (zh)
CN (2) CN104507926B (zh)
AR (2) AR090220A1 (zh)
AU (1) AU2013225737B2 (zh)
BR (1) BR112014021634B1 (zh)
CA (1) CA2866086C (zh)
CL (1) CL2014002301A1 (zh)
CO (1) CO7081155A2 (zh)
CR (1) CR20140413A (zh)
CY (1) CY1120172T1 (zh)
DK (2) DK2820009T3 (zh)
ES (2) ES2665073T3 (zh)
HK (3) HK1204323A1 (zh)
HR (2) HRP20180591T1 (zh)
HU (2) HUE037423T2 (zh)
IL (2) IL234376A (zh)
LT (2) LT3321262T (zh)
MX (1) MX354675B (zh)
MY (1) MY191936A (zh)
NO (1) NO2945854T3 (zh)
NZ (1) NZ700314A (zh)
PE (1) PE20150666A1 (zh)
PH (3) PH12014501947B1 (zh)
PL (2) PL2820009T3 (zh)
PT (2) PT3321262T (zh)
RS (2) RS61500B1 (zh)
RU (1) RU2650501C2 (zh)
SG (1) SG11201405356QA (zh)
SI (2) SI3321262T1 (zh)
TW (1) TWI589569B (zh)
UA (1) UA116774C2 (zh)
WO (1) WO2013130976A1 (zh)
ZA (2) ZA201406688B (zh)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103635472B (zh) 2011-02-28 2018-01-12 阵列生物制药公司 丝氨酸/苏氨酸激酶抑制剂
RU2014108140A (ru) 2011-08-04 2015-09-10 Эррэй Биофарма Инк. Соединение на основе хинозолина в качестве ингибиторов серен-треониновых киназ
RS61500B1 (sr) 2012-03-01 2021-03-31 Array Biopharma Inc Inhibitori serinske/treoninske kinaze
CN104271569B (zh) * 2012-05-03 2016-08-24 霍夫曼-拉罗奇有限公司 作为lrrk2调节剂的吡唑氨基嘧啶衍生物
MX369989B (es) 2012-08-27 2019-11-27 Array Biopharma Inc Inhibidores de serina/treonina cinasa para el tratamiento de enfermedades hiperproliferativas.
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
RU2015114936A (ru) 2012-10-16 2016-12-10 Ф. Хоффманн-Ля Рош Аг Ингибиторы серин/треонинкиназы
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
JP6219507B2 (ja) 2013-11-01 2017-10-25 ノバルティス アーゲー キナーゼ阻害剤としてのアミノヘテロアリールベンズアミド
CA2932729C (en) * 2013-12-06 2021-02-23 Genentech, Inc. Serine/threonine kinase inhibitors
WO2015103137A1 (en) 2013-12-30 2015-07-09 Array Biopharma Inc. Serine/threonine kinase inhibitors
MX370906B (es) * 2013-12-30 2020-01-09 Genentech Inc Inhibidores de serina/treonina cinasa.
JP6525437B2 (ja) 2014-04-02 2019-06-05 インターミューン， インコーポレイテッド 抗線維性ピリジノン
CA2945098C (en) * 2014-04-09 2022-10-04 Genentech, Inc. Process for the manufacturing of medicaments
TWI704151B (zh) * 2014-12-22 2020-09-11 美商美國禮來大藥廠 Ｅｒｋ抑制劑
US9879029B2 (en) 2014-12-22 2018-01-30 Eli Lilly And Company ERK inhibitors
CN107849046B (zh) * 2015-06-03 2020-06-12 常州捷凯医药科技有限公司 作为erk抑制剂的杂环化合物
AU2015396809B2 (en) * 2015-06-03 2019-07-11 Js Innopharm (Shanghai) Ltd. Heterocyclic compounds for treating psoriasis
CA3001799A1 (en) 2015-10-21 2017-04-27 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
EP3365335B1 (en) * 2015-10-23 2024-02-14 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
PT3374359T (pt) 2015-11-09 2020-03-27 Astrazeneca Ab Derivados de di-hidroimidazopirazinona úteis no tratamento do cancro
WO2017087905A1 (en) 2015-11-20 2017-05-26 Denali Therapeutics Inc. Compound, compositions, and methods
US11028080B2 (en) 2016-03-11 2021-06-08 Denali Therapeutics Inc. Substituted pyrimidines as LRKK2 inhibitors
CN109072311A (zh) 2016-04-15 2018-12-21 豪夫迈·罗氏有限公司 用于癌症的诊断和治疗方法
PT3472153T (pt) 2016-06-16 2021-12-31 Denali Therapeutics Inc Pirimidin-2-ilamino-1h-pirazóis como inibidores de lrrk2 para uso no tratamento de distúrbios neurodegenerativos
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
WO2019037640A1 (en) * 2017-08-22 2019-02-28 Js Innopharm (Shanghai) Ltd HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USING THE SAME
EP3679159A1 (en) 2017-09-08 2020-07-15 H. Hoffnabb-La Roche Ag Diagnostic and therapeutic methods for cancer
CU20200035A7 (es) 2017-11-24 2021-03-11 Novartis Ag Compuestos derivados de piridin-2-ona (6´-oxo-1´,6´dihidro) sustituidos como inhibidores selectivos de alk-2
CN111683928B (zh) * 2018-02-08 2021-12-10 漳州片仔癀药业股份有限公司 作为fgfr抑制剂的吡嗪-2(1h)-酮类化合物
EP3752200A1 (en) 2018-02-13 2020-12-23 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
EP3797109A4 (en) * 2018-05-22 2022-02-23 JS Innomed Holdings Ltd. HETEROCYCLIC COMPOUNDS USED AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF
JP2022527744A (ja) * 2019-03-28 2022-06-06 ジエンス ヘンルイ メデイシンカンパニー リミテッド チエノ複素環式誘導体、この誘導体のための調製方法及び医療に関するこの誘導体の使用
CN113784970B (zh) * 2019-05-15 2022-11-29 南京明德新药研发有限公司 Erk抑制剂及其应用
CN114206883A (zh) 2019-08-02 2022-03-18 伟迈可生物有限公司 氧代吡啶稠环衍生物及包含该衍生物的药物组合物
WO2022100586A1 (zh) * 2020-11-11 2022-05-19 南京明德新药研发有限公司 一种含氧杂环丁烷的螺环类化合物的晶型、制备方法及其应用
CN115413669B (zh) * 2022-06-14 2024-03-15 湖南大学 激酶抑制剂及其组合剂在提高植物青枯病抗性中的应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU693475B2 (en) 1993-10-01 1998-07-02 Novartis Ag Pyrimidineamine derivatives and processes for the preparation thereof
US5705502A (en) * 1993-10-01 1998-01-06 Novartis Corporation Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
CN1328277C (zh) 1996-12-05 2007-07-25 安姆根有限公司 取代的嘧啶酮和吡啶酮化合物和它们的应用
US6602872B1 (en) * 1999-12-13 2003-08-05 Merck & Co., Inc. Substituted pyridazines having cytokine inhibitory activity
ATE293962T1 (de) 2000-02-25 2005-05-15 Hoffmann La Roche Adenosin-rezeptor modulatoren
EP1283056B1 (en) 2000-04-26 2004-12-15 Eisai Co., Ltd. Medicinal compositions promoting bowel movement
WO2001083448A2 (de) 2000-05-02 2001-11-08 Tietze Lutz F Neue prodrugs von 6-hydroxy-2,3-dihydro-1h-indolen, 5-hydroxy-1,2-dihydro-3h-pyrrolo[3,2-e]indolen und 5-hydroxy-1,2-dihydro-3h-benzo[e]indolen sowie von 6-hydroxy-1,2,3,4-tetrahydro-benzo[f]chinolin-derivaten für eine selektive krebstherapie
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
TWI330183B (zh) * 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
US20050043315A1 (en) * 2002-01-02 2005-02-24 Hideo Tsutsumi Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them
CN100486576C (zh) * 2002-02-14 2009-05-13 法玛西雅公司 作为p38map激酶调节剂的取代吡啶酮类
AU2003234628B2 (en) * 2002-05-21 2007-08-23 Amgen Inc. Substituted heterocyclic compounds and methods of use
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
US7208498B2 (en) 2002-07-15 2007-04-24 Merck & Co., Inc. Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
US20050014753A1 (en) 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
CL2004002050A1 (es) * 2003-08-13 2005-06-03 Pharmacia Corp Sa Organizada B Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros.
TW200533357A (en) 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
JP2007532669A (ja) 2004-04-13 2007-11-15 イカジェン インコーポレイテッド カリウムイオンチャネル調節剤としての多環式ピリミジン
US7429604B2 (en) * 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
WO2006021458A2 (en) 2004-08-27 2006-03-02 Gpc Biotech Ag Pyrimidine derivatives
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
WO2006113704A2 (en) 2005-04-18 2006-10-26 Neurogen Corporation Subtituted heteroaryl cb1 antagonists
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US7572809B2 (en) 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
KR20080103996A (ko) 2006-02-16 2008-11-28 쉐링 코포레이션 Ｅｒｋ 억제제로서 피롤리딘 유도체
WO2007125405A2 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
DE102006035202A1 (de) 2006-07-29 2008-01-31 Lanxess Deutschland Gmbh Konservierungsmittel auf Basis von Carbonsäureanhydriden
US20100292205A1 (en) 2006-08-23 2010-11-18 Pfizer Inc. Pyrimidone Compounds As GSK-3 Inhibitors
WO2008039882A1 (en) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
EA200900799A1 (ru) 2006-12-22 2009-12-30 Новартис Аг Гетероарилгетероарильные соединения как ингибиторы cdk, предназначенные для лечения рака, воспаления и борьбы с вирусными инфекциями
TWI455936B (zh) 2007-02-01 2014-10-11 Tibotec Pharm Ltd 用於製備ｈｃｖ之大環蛋白酶抑制劑之方法及中間物
CA2685588A1 (en) 2007-06-08 2008-12-11 Bayer Cropscience Sa Fungicide heterocyclyl-pyrimidinyl-amino derivatives
PT2200436E (pt) 2007-09-04 2015-04-29 Scripps Research Inst Pirimidinilaminas substituídas como inibidoras da proteína quinase
MX2010005033A (es) 2007-11-06 2010-05-27 Du Pont Aminas heterociclicas fungicidas.
RU2525389C2 (ru) 2008-02-21 2014-08-10 Мерк Шарп И Доум Корп. Соединения, которые являются ингибиторами erk
US20090246198A1 (en) 2008-03-31 2009-10-01 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
EA201100049A1 (ru) 2008-06-27 2011-08-30 Новартис Аг Органические соединения
MX360970B (es) 2008-06-27 2018-11-23 Avila Therapeutics Inc Compuestos de heteroarilo y usos de los mismos.
EP2370413B1 (en) * 2008-12-08 2015-08-05 Arena Pharmaceuticals, Inc. Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
DE102009051799B4 (de) 2009-11-03 2021-07-01 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Bifunktionale Prodrugs und Drugs
DE102009060175A1 (de) 2009-12-23 2011-06-30 Merck Patent GmbH, 64293 Pyrrolo[2,3-d] pyrazin-7-yl-pyrimidin-Verbindungen
WO2012020786A1 (ja) * 2010-08-11 2012-02-16 日本新薬株式会社 医薬組成物
CN103635472B (zh) 2011-02-28 2018-01-12 阵列生物制药公司 丝氨酸/苏氨酸激酶抑制剂
CN102250065B (zh) * 2011-05-20 2015-05-13 浙江海正药业股份有限公司 取代的三嗪苯脲衍生物及其用途
RU2014108140A (ru) 2011-08-04 2015-09-10 Эррэй Биофарма Инк. Соединение на основе хинозолина в качестве ингибиторов серен-треониновых киназ
RS61500B1 (sr) * 2012-03-01 2021-03-31 Array Biopharma Inc Inhibitori serinske/treoninske kinaze
MX369989B (es) 2012-08-27 2019-11-27 Array Biopharma Inc Inhibidores de serina/treonina cinasa para el tratamiento de enfermedades hiperproliferativas.
KR102244553B1 (ko) 2013-08-23 2021-04-23 가부시키가이샤 한도오따이 에네루기 켄큐쇼 용량 소자 및 반도체 장치
US9532987B2 (en) * 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
MX370906B (es) * 2013-12-30 2020-01-09 Genentech Inc Inhibidores de serina/treonina cinasa.
WO2015103137A1 (en) * 2013-12-30 2015-07-09 Array Biopharma Inc. Serine/threonine kinase inhibitors
CA2945098C (en) * 2014-04-09 2022-10-04 Genentech, Inc. Process for the manufacturing of medicaments

Also Published As

Publication number Publication date
ZA201508847B (en) 2023-01-25
ES2665073T3 (es) 2018-04-24
PH12015501654A1 (en) 2017-04-10
US8697715B2 (en) 2014-04-15
CN106349217B (zh) 2020-08-28
PT3321262T (pt) 2021-03-04
RS57097B1 (sr) 2018-06-29
HRP20180591T1 (hr) 2018-05-18
HRP20210482T1 (hr) 2021-05-14
DK3321262T3 (da) 2021-01-25
IL234376A (en) 2016-10-31
CY1120172T1 (el) 2018-12-12
US9708290B2 (en) 2017-07-18
RS61500B1 (sr) 2021-03-31
US10519126B2 (en) 2019-12-31
TWI589569B (zh) 2017-07-01
SI2820009T1 (en) 2018-05-31
LT3321262T (lt) 2021-06-10
PL3321262T3 (pl) 2021-06-28
CR20140413A (es) 2014-11-05
ES2857649T3 (es) 2021-09-29
KR102093526B1 (ko) 2020-03-25
EP2820009B1 (en) 2018-01-31
US20180127393A1 (en) 2018-05-10
MX2014010432A (es) 2015-02-04
AR090220A1 (es) 2014-10-29
IL244276A0 (en) 2016-04-21
EP2820009A1 (en) 2015-01-07
HK1254429A1 (zh) 2019-07-19
PH12015501654B1 (en) 2017-04-10
BR112014021634B1 (pt) 2022-09-27
MY191936A (en) 2022-07-19
LT2820009T (lt) 2018-05-10
US9259470B2 (en) 2016-02-16
US20160122316A1 (en) 2016-05-05
PH12014501947A1 (en) 2014-11-24
US20140249127A1 (en) 2014-09-04
HK1204323A1 (zh) 2015-11-13
CO7081155A2 (es) 2014-10-10
PH12015501653A1 (en) 2017-04-10
RU2650501C2 (ru) 2018-04-16
NZ700314A (en) 2016-08-26
MX354675B (es) 2018-03-15
JP6068515B2 (ja) 2017-01-25
SI3321262T1 (sl) 2021-04-30
PE20150666A1 (es) 2015-05-06
PL2820009T3 (pl) 2018-09-28
EP3321262A1 (en) 2018-05-16
TW201339146A (zh) 2013-10-01
US20130252934A1 (en) 2013-09-26
ZA201406688B (en) 2017-08-30
HUE053994T2 (hu) 2021-08-30
CA2866086C (en) 2020-06-09
CN104507926A (zh) 2015-04-08
CL2014002301A1 (es) 2015-05-08
DK2820009T3 (en) 2018-04-16
UA116774C2 (uk) 2018-05-10
HK1206011A1 (zh) 2015-12-31
JP2015508828A (ja) 2015-03-23
IL244276B (en) 2020-01-30
KR20140138820A (ko) 2014-12-04
PH12015501653B1 (en) 2017-04-10
CA2866086A1 (en) 2013-09-06
AU2013225737B2 (en) 2018-03-01
PH12014501947B1 (en) 2014-11-24
JP2016027053A (ja) 2016-02-18
PT2820009T (pt) 2018-04-12
HUE037423T2 (hu) 2018-08-28
WO2013130976A1 (en) 2013-09-06
BR112014021634A8 (pt) 2018-01-30
CN106349217A (zh) 2017-01-25
EP3321262B1 (en) 2021-01-13
CN104507926B (zh) 2016-08-31
AR121879A2 (es) 2022-07-20
RU2014139601A (ru) 2016-04-20
SG11201405356QA (en) 2014-11-27

Similar Documents

Publication Publication Date Title
NO2945854T3 (zh)
BR112014017635A2 (zh)
BR112014018533A2 (zh)
BR112014017659A2 (zh)
BR112014017646A2 (zh)
AR092201A1 (zh)
BR112014017638A2 (zh)
BR112014024014A2 (zh)
BR112014017634A2 (zh)
BR112014017644A2 (zh)
BR112014017647A2 (zh)
BR112014019457A2 (zh)
BR112014017618A2 (zh)
BR112014017630A2 (zh)
BR112014017652A2 (zh)
BR112014017621A2 (zh)
BR112014018302A2 (zh)
BR112014017627A2 (zh)
BR112014017623A2 (zh)
BR112014017641A2 (zh)
BR112014017631A2 (zh)
BR112014017636A2 (zh)
BR112014019948A2 (zh)
BR112014017667A2 (zh)
BR112014017671A2 (zh)